VRTX Q2 Earnings: $3.33B Beat, Povetacicept PDUFA Nov 30

Vertex Pharmaceuticals (VRTX) reported second quarter 2026 revenue of $3.33 billion, up 12% year over year, beating consensus and prompting the company to raise full-year guidance to $13.1 to $13.2 billion from $12.95 to $13.1 billion. The FDA also accepted the biologics license application for povetacicept in IgA nephropathy with a PDUFA date of November 30, 2026, setting up Vertex’s first regulatory decision outside cystic fibrosis.

Vertex closed at $477.10 on August 1, valuing the company at roughly $121 billion, between Regeneron ($114B) and Gilead ($162B) among large-cap biotechs. The stock has been under pressure since the pending $10 billion Crinetics acquisition announcement, but Q2 numbers show the core business is intact.

The Numbers

The cystic fibrosis franchise still does the heavy lifting, generating $3.21 billion of the $3.33 billion total. Trikafta contributed $2.50 billion, down 2% year over year as patients switch to Alyftrek. Alyftrek ramped to $574 million from $157 million a year ago. The real growth story is outside CF. CASGEVY, the Casgevy CRISPR gene therapy for sickle cell disease and beta thalassemia, hit $76 million in Q2, up 78% sequentially and 151% year over year, benefiting from the pediatric expansion approved July 1. JOURNAVX, the non-opioid pain drug, reached $50 million, up 71% from Q1, with roughly 535,000 prescriptions filled in the quarter and PBM coverage now reaching about 260 million covered lives.

Povetacicept: The Next Binary Catalyst

The November 30 PDUFA for povetacicept is the headline catalyst. The BLA is supported by Week 36 interim data from the Phase 3 RAINIER trial, where povetacicept delivered a 52% reduction in proteinuria from baseline and a 49.8% reduction versus placebo (P < 0.0001). The drug also drove a 79.3% reduction in galactose-deficient IgA1, the disease-driving biomarker, and resolved hematuria in 85% of patients versus 23% on placebo. Vertex is using a priority review voucher for the six-month review.

Povetacicept is a dual BAFF/APRIL inhibitor, the same mechanism class as Vera Therapeutics’ Trutakna, which received accelerated approval on July 7. If approved, povetacicept would enter a crowded IgAN field that already includes Novartis’ Fabhalta (traditional approval), Otsuka’s Voyxact, and Vera’s Trutakna. Vertex’s differentiators are every-four-week dosing via low-volume autoinjector and the depth of its proteinuria data. The company is also advancing povetacicept in primary membranous nephropathy (Phase 3 OLYMPUS) and generalized myasthenia gravis (Phase 2).

The risk: the RAINIER interim data uses proteinuria as a surrogate endpoint. The FDA could require confirmatory eGFR data before converting an accelerated approval to traditional. Povetacicept was well tolerated in RAINIER. The most common adverse events were upper respiratory tract infections, nasopharyngitis, and injection site reactions, with no treatment-related serious adverse events. The BAFF/APRIL dual-inhibition mechanism carries unknown long-term immunosuppression risk.

What to Watch Next

The povetacicept approval decision on November 30 is the near-term binary. A yes would launch Vertex’s nephrology franchise and validate the BAFF/APRIL dual-inhibitor mechanism across multiple autoimmune kidney diseases. A no would narrow the pipeline back to CF, pain, or gene therapy. The Crinetics deal close, expected in Q3, adds a fifth pillar in rare endocrine diseases. Vertex also has pipeline readouts later in 2026: VX-670 in myotonic dystrophy and inaxaplin in APOL1-mediated kidney disease.

Source: Vertex Q2 2026 Financial Results press release